ProRx LLC in Exton, PA, is the most heavily sanctioned partner, with two FDA Warning Letters (March 2025 and April 2026), two voluntary sterile-product recalls covering compounded tirzepatide and semaglutide in August 2024 and October 2025, an open FDA 483 from September/October 2025, and an explicit FDA warning of possible seizure or injunction
[35], demonstrated that while LSG induces significant increases in fasting GLP-1 levels at 1, 3, 6, and 12 months postoperatively, these changes are less pronounced than those following RYGB
When you drink, alcohol triggers a release of feel-good chemicals through the brain's opioid receptors, and naltrexone blocks those receptors
APS-3 commonly involves combinations of HT with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjgrens syndrome, or T1D
It's time to leverage innovative therapies that deliver powerful glycemic control, significant weight loss, and proven cardiovascular protection